BOSTON, Jan. 4, 2018 /PRNewswire/ — Neurogastrx, Inc., a private biopharmaceutical company focused on discovering and developing therapies for gastrointestinal disorders affecting the enteric nervous system, today announced a transformative $45M Series A financing co-led by 5AM Ventures,…
